News

PTC Releases Data On New SMA Drug

PTC Therapeutics recently announced the release of clinical data from their Phase I trial testing the effects of the company’s oral formulation RG7800 to improve the status of spinal muscular atrophy (SMA) patients. The study entitled “SMN2 splicing modifier RG7800 shows dose-dependent increase of full length SMN2 mRNA in first-in-human study” was…

Cure SMA Releases Booklet on Musculoskeletal System

The nonprofit organization Cure SMA has released another one of its booklets focused on improving care for patients with spinal muscular atrophy (SMA). This edition, which is entitled “The Musculoskeletal System” and included in the organization’s care series booklets, aims to increase knowledge on muscles…

Cure SMA Releases Online Publication on Research Grantees

The non-profit organization Cure SMA has released the Spring 2015 issue of Compass, its research publication on the organization’s mission and most recent updates. Compass is a newsletter and online publication available for download that intends to increase the knowledge of patients who suffer from…

Over $100,000 Donated for SMA at Muscles for Mckenna Gala

Jim, Mckenna and Amy Ellixson The Annual Muscles for Mckenna Gala was held for the third year in Philadelphia, Pennsylvania and has raised $107,000 in donations to support the non-profit organization Cure SMA. It is still possible to donate to help the organization reach the $115,000 goal, as the funding will finance…

SMA Patient Muscle is Deficient in Mitochondrial Biogenesis

Patients with spinal muscular atrophy (SMA) exhibit many signs of mitochondrial paucity. Weakened muscles and other pathologic muscle changes are accompanied by decreased levels of mitochondrial DNA (mtDNA) and decreased levels of mitochondrial respiratory chain complex proteins, such as complex II. Although all signs lead to decreased levels of…

SMA Severity Correlates with DNA Methylation

Patients with spinal muscular atrophy (SMA) are subdivided into four categories based on disease severity and age of diagnosis, with type I the most severe and diagnosed in infancy and type IV the least severe and diagnosed in adulthood. It is known that the copy number of SMN2 genes…

Cure SMA Launches New Chapter in Virginia

The nonprofit organization Cure SMA has announced the launch of a new chapter based in Virginia. The new Cure SMA Virginia Chapter will not only serve residents of the state, but also those with the disease and their families in Washington DC. The establishment of the Virginia chapter…